This study will evaluate the recommended dose for further clinical development, safety,
tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of
IKS014, a HER2 targeting antibody-drug conjugate, in patients with advanced solid tumors.